Geneoscopy Resolves Patent and False Advertising Litigation with Exact Sciences Following a Series of Victories at the Patent Trial and Appeal Board

All pending Delaware litigation dismissed with no admission of liability or wrongdoing

ST. LOUIS — (Nov. 17) — Geneoscopy, Inc., a healthcare diagnostics company advancing the next generation of tools for gastrointestinal health, including ColoSense, its noninvasive colorectal cancer screening test, today announced the resolution of all pending district court litigation with Exact Sciences Corporation.

Exact Sciences and Geneoscopy have settled the consolidated litigation in the U.S. District Court for the District of Delaware, and the court has dismissed all claims and counterclaims. The settlement is not an admission of liability or wrongdoing by either party. Settlement terms are otherwise confidential.

Geneoscopy achieved a string of victories at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office during the parties' dispute. In July 2025, the PTAB found all 20 challenged claims of Exact Sciences' U.S. Patent No. 11,634,781 unpatentable as obvious. In August 2025, after Geneoscopy prevailed at the PTAB, Exact Sciences withdrew its July 2024 motion for a preliminary injunction seeking to keep ColoSense off the market. In February 2026, Geneoscopy prevailed again before the PTAB, which found all 10 challenged claims of U.S. Patent No. 11,970,746 unpatentable as obvious. As a result, the Patent Office determined that every patent claim Exact Sciences asserted against Geneoscopy in litigation was invalid.

In accordance with the parties' stipulation of dismissal, the District Court has, among other things, dismissed with prejudice all patent claims Exact Sciences asserted against the commercial version of Geneoscopy's ColoSense. In addition, the District Court dismissed with prejudice all of Exact Sciences' claims that Geneoscopy engaged in false or misleading advertising in promoting ColoSense.

"From the beginning, we have remained confident in our innovative science, the strength of our intellectual property, the advantages of our RNA-based technology, and the advances in convenience ColoSense offers patients," said Andrew Barnell, co-founder and chief executive officer of Geneoscopy. "With the termination of litigation that never should have been brought and the PTAB's invalidation of patents that never should have issued, we can now shift our focus to where it belongs: putting ColoSense within reach of every eligible patient."

Going forward, Geneoscopy will continue to expand access to ColoSense and advance its pipeline of RNA-based tests for other gastrointestinal conditions, including inflammatory bowel disease.

About ColoSense®
ColoSense is Geneoscopy's FDA-approved, multi-target stool RNA test for the qualitative detection of colorectal neoplasia-associated RNA markers and occult hemoglobin in human stool. Geneoscopy developed ColoSense as a noninvasive colorectal cancer (CRC) screening option for average-risk adults 45 and older. ColoSense is listed as a preferred screening option in the American Cancer Society colorectal cancer screening guidelines and included in the National Comprehensive Cancer Network (NCCN) Guidelines. A positive ColoSense result should be followed by appropriate diagnostic evaluation, including colonoscopy, as determined by a healthcare provider. ColoSense is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals. ColoSense is available nationwide. For more information, visit colosense.com.

About Geneoscopy
Geneoscopy is a healthcare diagnostics company focused on advancing gastrointestinal health by designing tools for real-world care. The company's proprietary, patented RNA-based biomarker platform powers its FDA-approved ColoSense test for CRC screening and supports continued development of clinically useful diagnostic tools for gastrointestinal health. For more information, visit geneoscopy.com.

###

MEDIA CONTACT
media@geneoscopy.com

INVESTOR RELATIONS CONTACT
Amit Bhalla, Chief Financial Officer
amit.bhalla@geneoscopy.com